can psychiatrists prescribe glp-1 Should GLP-1s? + Revenue Management Guide Medicare Bridge Program Explained: GLP-1

Medicare now covers GLP-1s for obesity

Devices must include high-contrast labels and tactile features for those with visual or dexterity impairments

In announcing the program, the health secretary, Robert F Kennedy Jr, projected the American public would collectively lose 125m pounds by this time next year

What we know: Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously Phase 2/3 trials show 24-29% weight loss at highest doses Side effects are similar to other incretin medications (mainly GI) It may be particularly effective for liver fat reduction FDA approval is potentially years away What to consider: Approved alternatives (semaglutide, tirzepatide) have established safety profiles "GLP-3" marketing may oversimplify or mislead Investigational drugs carry unknown long-term risks Quality control for compounded versions is variable Clinical trial results don't always translate to real-world outcomes The bigger picture: Retatrutide may represent a genuine advance in obesity treatmentthe data is genuinely impressive

One Mayo Clinic Diet member, Donna Cooper, commented on the combined success of her weight loss along with improved health markers